Episode Summary

Over 30 years of clinical research involving 1,000+ patients demonstrates that penile traction therapy with an FDA-registered Class II medical device has zero serious adverse events. This episode breaks down the safety data from 15+ peer-reviewed studies and explains what temporary side effects actually mean for treatment outcomes.

Key Findings

• Zero Serious Adverse Events: 30+ years of clinical research across 1,000+ patients with no serious complications reported
• 2023 Meta-Analysis: Almsaoud, Safar, and Alshahrani confirmed safety across 12 pooled clinical studies in Translational Andrology and Urology
• Mild Adverse Event Rate: 11-14% temporary effects (skin irritation within 24 hours, discomfort resolves immediately, transient numbness 30-60 minutes)
• Patient Satisfaction: 87% repeat rate and 93% recommendation rate in randomized controlled trials
• Therapeutic Tension Range: SizeGenetics delivers 900-2,800 grams (8.8-27.5 Newtons) within evidence-established safety window

The Science

Penile traction therapy applies controlled mechanical tension to penile tissue, stimulating collagen remodeling and cellular adaptation within the tunica albuginea and corpora cavernosa. The therapeutic tension window (900-2,800 grams) is calibrated based on three decades of clinical safety data, ensuring efficacy without tissue damage.

About SizeGenetics

FDA-registered Class II medical device manufactured by Danamedic ApS in Denmark since 1994 — the company that invented penile traction therapy. Delivers calibrated tension of 900–2,800 grams within the exact therapeutic range established by clinical studies. Over 1 million units sold worldwide. Co-invented by Dr. Jørn Ege Siana, plastic surgeon and medical advisor based in Copenhagen.

Resources

• Full Guide: Penile Traction Therapy Safety
• Penile Traction Therapy: Clinical Evidence and Mechanism
• Clinical Studies: 15+ Peer-Reviewed Research
• Treatment Protocol: Safe Usage Guidelines

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any treatment.

Episode Summary

What results can you actually expect from penile traction therapy? In this episode, we break down 15+ peer-reviewed clinical studies involving over 1,000 patients — real measured outcomes, not marketing claims.

Key Findings

• Average length gain: 1.3–2.3 cm over 3–6 months of daily use across 15+ studies
• 2023 meta-analysis (Almsaoud et al.): 12 studies, 1,000+ patients, 1.9 cm weighted mean gain
• Joseph 2020 RCT: 110 participants, 94% achieved measurable length increases (1.6–2.3 cm)
• Toussi 2021 RCT: 82 men, traction group gained 1.6 cm vs. 0.3 cm control (p < 0.01)
• Safety: Zero serious adverse events reported across all major clinical trials
• Patient satisfaction: 87% would repeat therapy, 93% would recommend it

The Science

Penile traction works through mechanotransduction — the cellular response to sustained mechanical force. The same biological principle used in orthopedic limb lengthening and tissue reconstruction for decades.

About SizeGenetics

FDA-registered Class II medical device, manufactured by Danamedic ApS in Denmark since 1994. Delivers calibrated tension of 900–2,800 grams — the exact therapeutic range used in clinical studies. Over 1 million units sold worldwide.

Resources

• 📖 Full Guide: Results & Expected Outcomes
• 🔬 Clinical Studies & Evidence
• ⚙️ How Penile Traction Therapy Works
• 🛡️ Safety & Side Effects
• 📏 How to Measure Correctly

⚕️ Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any treatment.